Physician profile
Robert E Clutter
NPI 1578586277
$77,261.10
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $106 · 2022: $545 · 2023: $839 · 2024: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $75K · Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $74,816.48 |
| Food and Beverage | $1,201.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $74,816.48 | 2024 | |
| Novo Nordisk INC | $347.71 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $286.69 | 2022-2024 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $240.77 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $202.36 | 2019-2024 | Evenity, Prolia |
| Pfizer INC. | $157.96 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.96 | 2022-2024 | |
| Glaxosmithkline, LLC. | $104.89 | 2019-2023 | Shingrix, Arexvy |
| Lilly USA, LLC | $101.61 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Genzyme Corporation | $70.00 | 2019 | |
| Astellas Pharma US INC | $66.90 | 2019-2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.57 | 2019-2024 | Ofev |
| Abbott Laboratories | $52.62 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.74 | 2019 | |
| Antares Pharma, INC. | $49.62 | 2022-2023 | Tlando, Nocdurna, Xyosted |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.